MOLECULIN BIOTECH INC (MBRX) Forecast, Price Target & Analyst Ratings
NASDAQ:MBRX • US60855D4088
2.24 USD
-0.1 (-4.27%)
Last: Mar 5, 2026, 04:04 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MOLECULIN BIOTECH INC (MBRX).
Forecast Snapshot
Consensus Price Target
$24.82
+ 1,008.03% Upside
Next Earnings Forecast
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$6.23
Revenue Estimate
ChartMill Buy Consensus
82.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$24.82
Upside
+ 1,008.03%
From current price of $2.24 to mean target of $24.82, Based on 9 analyst forecasts
Low
$20.20
Median
$22.44
High
$32.55
Price Target Revisions
1 Month
-52.29%
3 Months
265.00%
Price Target Summary
9 analysts have analysed MBRX and the average price target is 24.82 USD. This implies a price increase of 1008.04% is expected in the next year compared to the current price of 2.24.
The average price target has been revised upward by 265% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
MBRX was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about MBRX.
In the previous month the buy percentage consensus was at a similar level.
MBRX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Maxim Group | Upgrade | Hold -> Buy |
| 2025-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-12 | Maxim Group | Maintains | Buy -> Buy |
| 2024-04-12 | Roth MKM | Maintains | Buy -> Buy |
| 2024-03-26 | Maxim Group | Maintains | Buy -> Buy |
| 2023-12-14 | HC Wainwright & Co. | Initiate | Buy |
| 2023-04-18 | Roth MKM | Maintains | Buy |
| 2023-03-24 | Oppenheimer | Reiterate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$6.23
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q33.17%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-3,391.43%
Next Earnings Summary
MBRX is expected to report earnings on 3/19/2026. The consensus EPS estimate for the next earnings is -6.23 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 121.76% | N/A 32.72% | N/A 19.50% | N/A 34.63% | |||||||||||
| EBITDA YoY % growth | -454K | -3.877M -753.96% | -8.635M -122.72% | -14.957M -73.21% | -17.325M -15.83% | -19.542M -12.80% | -22.804M -16.69% | -30.51M -33.79% | -29.504M 3.30% | -26.515M 10.13% | N/A 2.67% | N/A -9.09% | N/A -17.39% | N/A 68.52% | N/A 465.69% | N/A 111.80% | N/A 83.16% | N/A | N/A | |
| EBIT YoY % growth | -465.3K | -3.883M -734.56% | -8.653M -122.83% | -15.025M -73.64% | -17.524M -16.63% | -19.742M -12.66% | -22.968M -16.34% | -30.64M -33.40% | -29.631M 3.29% | -26.641M 10.09% | N/A 6.61% | N/A -14.18% | N/A -3.53% | N/A -5.11% | N/A 174.23% | N/A 286.48% | N/A 53.03% | N/A 24.28% | N/A 25.90% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A -46.88% | -1,035.00 4.05% | -765.00 26.09% | -660.00 13.73% | -221.25 66.48% | -378.75 -71.19% | -376.75 0.53% | -173.58 53.93% | N/A 78.64% | N/A 79.37% | N/A 47.78% | N/A -7.79% | N/A 193.60% | N/A 167.34% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | |
|---|---|---|
| EPS Q2Q % growth | -6.23 33.17% | -3.22 81.31% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | -7.854M -20.52% | N/A |
| EBIT Q2Q % growth | -5.955M 10.36% | -7.161M -20.50% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.51%
EPS Next 5 Year
15.14%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-6.25%
EBIT Next 5 Year
27.59%
MOLECULIN BIOTECH INC / MBRX Forecast FAQ
Can you provide the average price target for MOLECULIN BIOTECH INC stock?
9 analysts have analysed MBRX and the average price target is 24.82 USD. This implies a price increase of 1008.04% is expected in the next year compared to the current price of 2.24.
What is the next earnings date for MBRX stock?
MOLECULIN BIOTECH INC (MBRX) will report earnings on 2026-03-19, after the market close.
What are the consensus estimates for MBRX stock next earnings?
The consensus EPS estimate for the next earnings of MOLECULIN BIOTECH INC (MBRX) is -6.23 USD and the consensus revenue estimate is 0 USD.
How many analysts cover MOLECULIN BIOTECH INC (MBRX) stock?
The number of analysts covering MOLECULIN BIOTECH INC (MBRX) is 9.